Patients who require paralysis with cisatracurium as part of their clinical care in ICU

Critical Illness

Respiratory Distress Syndrome, Adult

Neuromuscular Blockade

Respiratory Failure

Paralysis

ARDS, Human

A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).

cisatracurium

Faculty of Medicine Ramathibodi Hospital

The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium

The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients

Data will be collected in case-record form and managed by Microsoft Office Excel. Statistical analyses will be performed using SPSS.

Analysis of time to maximum concentration will be performed with a nonlinear mixed-effects population modelling approach as implemented in NONMEM software.

Analysis of half-life will be performed with a nonlinear mixed-effects population modelling approach as implemented in NONMEM software.

Analysis of clearance will be performed with a nonlinear mixed-effects population modelling approach as implemented in NONMEM software.

Analysis of elimination rate constant will be performed with a nonlinear mixed-effects population modelling approach as implemented in NONMEM software.

Panadda Panusitthikorn

Principal Investigator

Mahidol University

To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.

Traumatic Brain Injury

Intracranial Hypertension

cisatracurium besilate

Placebo

CHU de Clermont-Ferrand

Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents

Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents. A Controlled Randomized Study Versus Placebo

The primary outcome is the area under the curve of the temporal evolution of intracranial pressure, over a period of 30 minutes after the administration of neuromuscular blocking agent or placebo.

diffuse axonal injury, subarachnoid hemorrhage, intracerebral hematoma)

acute respiratory distress syndrome, pneumonia acquired under mechanical ventilation

laudanosine/hüpotermia

The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium

Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus